Genesis Global Group
Genesis Drug Discovery & Development
GD3

You will now be redirected to the GD3 website

Genesis Drug Discovery & Development is a proud member of Genesis Drug Discovery & Development (GD3), a fully integrated CRO providing services to support drug discovery programs of our clients from target discovery through IND filing and managing Phase I-III clinical trials.

Learn more about GD3
Search

Disease Modeling

Contact our Experts

Patient-derived xenografts (PDX) are models of cancer where the tissue or cells from a patient's tumor are implanted directly into an animal model. PDX models are important preclinical tools for developing effective and safe therapeutics that combat cancer. Drug developers can utilize PDX models to target patient tumors with specific oncogene profiles. PDX models are significantly more accurate in predicting clinical efficacy than other, more conventional approaches. This predictive accuracy helps our clients develop successful drug candidates by providing a more accurate assessment of therapeutic efficacy, thereby enabling better decision-making and allocation of time and resources.

With GD3 clients receive a boutique experience with highly skilled experts customized for their study.

Is this right for you? Contact us to speak with one of our experts to start building your study.

Request a Quote

Learn more about

Our unique collections of patient-derived xenograft (PDX) models used to evaluate safety and efficacy include:

  • Pancreatic Ductal Adenocarcinoma (PDAC) Pancreatic Cancer PDX Collection - in vivo screening for drug efficacy, tumor kinetics and animal survival studies
  • Gastrointestinal (GI) PDX Collection (Esophageal, Gastric, Colorectal and liver cancer models) - histological analysis and SOC studies
  • Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung cancer (SCLC) and Mesothelioma PDX Collection - WES - mutational and RNA-seq gene expression analysis for model selection
  • Lymphoma PDX Collection – SOC studies, subcutaneous (SQ) and disseminating implantation studies
  • Bladder Cancer PDX Collection – application of PDX models for immune-oncology
  • Radiation Therapy Core –RT/drug combination studies with combinations of chemotherapies, targeted agents, and immune-oncology drugs with whole body and focal radiation therapy

Custom Models

GD3 offers to create PDX models based on the specific customer request. These models might be developed on exclusive and nonexclusive basis from primary and metastatic lesions with regard to patient ethnicity, medical history and treatment protocols.

PDX Discovery Platform

PDX models with established KRAS gene mutations

PNX Model # Tumor Type Gene Name Protein Change DNA Change
PNX0079 Endometrium KRAS p.G12V c.35G>T
PNX0128 Endometrium KRAS p.Q61H c.183A>C
PNX0285 Gastric KRAS p.G12D c.35G>A
PNX0314 Rectum KRAS p.Q61H c.183A>T
PNX0314 Rectum KRAS p.G13C c.37G>T
PNX0419 Colon KRAS p.G13D c.38G>A
PNX0435 Colon KRAS p.G12D c.35G>A
PNX0001 Pancreatic KRAS p.G12V c.35G>T
PNX0017 Pancreatic KRAS p.G12D c.35G>A
PNX0045 Pancreatic KRAS p.G12D c.35G>A
PNX0050 Pancreatic KRAS p.Q61H c.183A>C
PNX0050 Pancreatic KRAS T58I c.173C>T
PNX0055 Pancreatic KRAS p.G12D c.35G>A
PNX0059 Pancreatic KRAS p.G12D c.35G>A
PNX0060 Pancreatic KRAS p.G12D c.35G>A
PNX0159 Pancreatic KRAS p.G12D c.35G>A
PNX0167 Pancreatic KRAS G12R c.34G>C
PNX0174 Pancreatic KRAS p.G12D c.35G>A
PNX0175 Pancreatic KRAS G12R c.34G>C
PNX0195 Pancreatic KRAS p.G12V c.35G>T
PNX0197 Pancreatic KRAS p.G12D c.35G>A
PNX0230 Pancreatic KRAS G12R c.34G>C
PNX0278 Pancreatic KRAS p.G12D c.35G>A
PNX0296 Pancreatic KRAS p.G12D c.35G>A
PNX0302 Pancreatic KRAS p.G12D c.35G>A
PNX0362 Pancreatic KRAS p.G12V c.35G>T
PDX Discovery Platform Illustration
  • IRB 12-822
  • Patient-derived xenografts (PDX)
  • Xenopatient Trials of New Drugs
  • Active Drugs
  • Validation in GEM
  • Path to Clinical Trials

Examples of Study Services

Two Mesothelioma PDX Models Formed Tumors in Humanized Mice

Graph 1
Graph 2
  • huMice models provide an opportunity to investigate response to immuno-oncology agents
  • 11 mesothelioma PDX models available

Two Lung NSCLC PDX Models in Humanized Mice

Graph 3
Graph 4
  • Two GD3 Lung PDX models demonstrate sensitivity to the immuno-oncology agent pembrolizumab in humanized mice
  • 5 Nexus Pharma Lung PDX models established tumor growth in huCD34 NCG mice

Two Bladder Cancer PDX Models in Humanized Mice

Graph 5
Graph 6
  • Two GD3 Bladder PDX models demonstrate differential sensitivity to the immuno-oncology agent pembrolizumab and standard of care drug cisplatin in humanized mice
  • 4 GD3 Bladder PDX models established tumor growth in huCD34 NCG micee

SOC Treatment in a Subset of Colon, Rectal, and Small Intestine PDX Models

Graph 7
Graph 8
Graph 9
  • Strong correlation with patient responses to the treatment for all tested agents

RNASEQ analysis of differential gene expression in GD3 PDX models

Graph 10
  • Biomarker analysis using gene expression data allows our clients to select the most relevant PDX models for their studies
  • RNAseq data analysis available for 78 PDX models and next 21 models are in progress

Genomic Analysis Of PDX Models

ANTRX1 Gene Expression In a Subset of PDX Models

Relative mRNA Expression of ANTRXR1 in PDX Tumors

Graph 1: Relative mRNA Expression of ANTRXR1 in PDX Tumors

ANTRX1 Gene Expression in Various Tumor Types

mRNA Expression of ANTRX1 in Various Tumor Types

Graph 2: mRNA Expression of ANTRX1 in Various Tumor Type

Data Analysis

over 150 PDX models established

Validation with SOC

(for selected model)

Patient Icon

Molecular Characterization

  • IHC
  • Targeted gene expression profiling
  • Gene Mutation analysis by WES and NGS gene panels

Patient Data

Graph 3: Data Analysis